(24S)-Ginsenoside V
(24S)-Ginsenoside V is a monooxygenated derivative of Ginsenoside Rb1 (HY-N0039). (24S)-Ginsenoside V is the major circulating metabolite of Ginsenoside Rb1 in rat plasma. (24S)-Ginsenoside V appears in rat urine after intravenous and oral administration of Ginsenoside Rb1 to rats.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1679350-46-9
- Formule: C54H92O24
- Masse moléculaire:1125.29
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1679350-46-9
-
Masse moléculaire 1125.29
-
Formule C54H92O24
-
SMILES
C[C@]12[C@]3([C@@]([C@@H](C[C@]1([H])[C@@]4([C@@](C(C)([C@H](CC4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@@H]6O[C@@H]([C@H]([C@@H]([C@H]6O)O)O)CO)C)([H])CC2)C)O)([H])[C@@](CC3)([H])[C@@](CC[C@H](O)C(C)=C)(C)O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O)CO[C@@H]8O[C@@H]([C@H]([C@@H]([C@H]8O)O)O)CO)C
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(24S)-Ginsenoside V Related Classifications
HY-N18029 Related Classifications
Powered by Bioz